Comparison of Two Dosing Regimens of Gabexate in the Prophylaxis of Post-ERCP Pancreatitis

American Journal of Gastroenterology

Volumn 98, Issue 10, 2003, Pages 2182-2186

  Masci, Enzo ^a   Cavallini, Giorgio ^b   Mariani, Alberto ^b   Frulloni, Luca ^b   Alberto Testoni, Pier ^b   Curioni, Simona ^b   Tittobello, Alberto ^b   Uomo, Generoso ^b   Costamagna, Guido ^b   Zambelli, Sandro ^b   Macarri, Gianpiero ^b   Innocenti, Paolo ^b   Dragonetti, Carola ^b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GABEXATE MESILATE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; HEADACHE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PANCREATITIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TACHYCARDIA;

EID: 0041842118     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07698.x     Document Type: Article

References (18)

1. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996;335: 909-18.
2. Loperfido S, Angelini G, Benedetti G, et al. Major early complications from diagnostic and therapeutic ERCP: A prospective multicenter study. Gastrointest Endosc 1998;48:1-10.
3. Masci E, Toti G, Mariani A, et al. Complications of diagnostic and therapeutic ERCP: A prospective multicenter study. Am J Gastroenterol 2001;96:417-23.
4. Freeman ML, Di Sario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: A prospective, multicenter study. Gastrointest Endosc 2001;54:425-34.
5. Cavallini G, Tittobello A, Frulloni L, et al. Gabexate for the prevention of pancreatic damage related to endoscopic retrograde choangiopancreatography. N Engl J Med 1996;335: 919-23.
6. Huibregtze K. Complications of endoscopic sphincterotomy and their prevention. N Engl J Med 1996;335:961-2.
7. Saluja A, Saluja M, Villa A, et al. Pancreatic duct obstruction in rabbits causes digestive zymogen and lysosomal enzyme colocalization. J Clin Invest 1989;84:1260-6.
8. Gottlieb K, Sherman S, Pezzi J, et al. Early recognition of post-ERCP pancreatitis by clinical assessment and serum pancreatic enzymes. Am J Gastroenterol 1996;91:1553-7.
9. Messmann H, Vogt W, Holstege A, et al. Post-ERCP pancreatitis as a model for cytokine-induced acute phase response in acute pancreatitis. Gut 1997;40:80-5.
10. LaFerla G, Gordon S, Archibald M, et al. Hyperamylasemia and acute pancreatitis following endoscopic retrograde cholangiopancreatography. Pancreas 1986;1:160-3.
11. Testoni PA, Bagnolo F, Caporuscio S, Lella F. Serum amylase measured four hours after endoscopic sphincterotomy is a reliable predictor of post-procedure pancreatitis. Am J Gastroenterol 1999;94:1235-9.
12. Bradley EL. A clinically based classification system for acute pancreatitis. Arch Surg 1993;128:586-90.
13. De Palma GD, Catanzano C. Use of corticosteroid in the prevention of post-ERCP pancreatitis: Results of a controlled prospective study. Am J Gastroenterol 1999;94:982-5.
14. Ohshio G, Saluja AK, Leli U, et al. Esterase inhibitors prevent lysosomal enzyme redistribution in two noninvasive models of experimental pancreatitis. Gastroenterology 1989;96:853-9.
15. Tham TCK, Vandervoort J, Wong RCK, et al. Therapeutic ERCP in outpatients. Gastrointest Endosc 1997;46:225-30.
16. Mehta SN, Pavone E, Barkun AN. Outpatients therapeutic ERCP: A series of 262 consecutive series. Gastrointest Endosc 1996;44:443-9.
17. Andriulli A, Clemente R, Solmi L, et al. Gabexate or somatostatin administration before ERCP in patients at risk for post-intervention pancreatitis: A placebo-controlled, randomized, clinical trial. Pancreatology 2001;1:129.
18. Pasha TM, Therneau T, Petersen BT. Economic analysis of gabexate mesylate in post-ERCP pancreatitis. Gastrointest Endosc 1997; 112 (suppl):A417 (abstract).